Alkermes plc (ALKS) Stock Price & Analysis
Alkermes plc (ALKS) closed at USD 44.18 on Thursday, October 22, 2026, up 1.61% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 43.48; the Oct 22, 2026 session ranged USD 43.46–44.68 on volume of 1,833,975 shares. Market capitalization is $7.41B, with a 52-week range of USD 27–55.67 (NMS). Source: Nexqual, retrieved October 23, 2026 at 11:23 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ALKS.md
Key facts (ALKS)
- Last four reported quarters (through Jun 30, 2026): revenue $1.67B, net income $66.1M (4.0% margin), free cash flow $222M (SEC filings).
- Valuation: P/E 112.1x (avg 15.3x at the last 3 fiscal year-ends), EV/EBITDA 46.3x, net debt $868M.
- Insider open-market sales, last ~7 months: 16 Form 4 filings, $6.0M; 2 not under a Rule 10b5-1 plan ($2.9M); 1 by opportunistic insiders (0 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.20 on a 1–5 scale) (20 analysts), mean target USD 56.21 (range 38–83).
- Total return with dividends: 1Y +47.1% vs S&P 500 +14.9%; 5Y +43.2% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 0.25, revenue estimate $465M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ALKS)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.17B | $1.11B | $1.66B | $1.56B | $1.48B | $1.67B |
| Gross profit | $976M | $894M | $1.41B | $1.31B | $1.28B | — |
| Operating income | $97.7M | -$6.1M | $414M | $421M | $254M | $117M |
| Net income | -$48.2M | -$158M | $356M | $367M | $242M | $66.1M |
| EPS (diluted) | -$0.29 | -$0.97 | $2.10 | $2.17 | $1.43 | — |
| Free cash flow | $73.7M | -$17.2M | $353M | $406M | $480M | $222M |
| Gross margin | 83.2% | 80.4% | 84.8% | 84.2% | 86.7% | — |
| Operating margin | 8.3% | -0.5% | 24.9% | 27.0% | 17.2% | 7.0% |
| Net margin | -4.1% | -14.2% | 21.4% | 23.6% | 16.4% | 4.0% |
| Revenue growth | +13.0% | -5.3% | +49.6% | -6.4% | -5.2% | — |
| Cash + short-term investments | $536M | $608M | $773M | $752M | $588M | — |
| Total debt | $296M | $293M | $291M | — | $0K | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ALKS)
P/E 112.1x · P/S 4.4x · EV/EBITDA 46.3x · EV/Sales 5.0x · P/FCF 33.4x · P/B 4.1x · FCF yield 2.99% · Earnings yield 0.89% · Net debt $868M · EV $8.28B
P/E at fiscal year-ends: Dec 2025 19.5x, Dec 2024 13.3x, Dec 2023 13.2x.
Insider sales (SEC Form 4, open-market, last ~7 months) (ALKS)
14 of 16 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | 2,034 | $83K | 0.9% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-03 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | 2,034 | $98K | 0.9% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | 9,000 | $423K | 12.1% | Yes | Too little history (no open-market trades in 2023) |
| 2026-08-17 | Nichols Christian Todd | SVP, Chief Commercial Officer | 7,576 | $373K | 6.9% | Yes | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-08-03 | Snyderman Nancy Lynn Md | Director | 44,472 | $2.2M | 55.1% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-03 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | 9,000 | $437K | 11.5% | Yes | Too little history (no open-market trades in 2023) |
| 2026-08-03 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | 2,034 | $99K | 0.9% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-07-06 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | 2,034 | $110K | 0.9% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-07-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | 9,000 | $464K | 10.9% | Yes | Too little history (no open-market trades in 2023) |
| 2026-06-12 | Wright Christopher I | Director | 2,000 | $90K | 7.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-06-04 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | 2,034 | $88K | 0.9% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-06-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | 9,000 | $375K | 10.4% | Yes | Too little history (no open-market trades in 2023) |
| 2026-05-29 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | 16,217 | $687K | 67.8% | No | Too little history (no open-market trades in 2023) |
| 2026-05-04 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | 2,034 | $68K | 0.9% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-05-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | 9,000 | $301K | 10% | Yes | Too little history (no open-market trades in 2023) |
| 2026-04-06 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | 2,034 | $70K | 0.9% | Yes | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (ALKS)
Consensus Buy (mean 2.20 on a 1–5 scale), 20 analysts; mean target USD 56.21 (low 38, high 83).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-22 | RBC Capital | Reiterated | Outperform | $56 |
| 2026-09-22 | Baird | Target raised | Outperform | $58 → $61 |
| 2026-09-21 | Needham | Reiterated | Buy | $62 |
| 2026-07-29 | JP Morgan | Target raised | Neutral | $60 → $61 |
| 2026-07-29 | Baird | Target raised | Outperform | $48 → $58 |
| 2026-07-28 | Piper Sandler | Target raised | Overweight | $43 → $65 |
| 2026-07-20 | Stifel | Target raised | Buy | $45 → $63 |
| 2026-07-13 | Needham | Target raised | Buy | $61 → $62 |
| 2026-07-02 | Mizuho | Target raised | Outperform | $53 → $65 |
| 2026-06-29 | Wells Fargo | Target raised | Overweight | $44 → $65 |
| 2026-06-29 | B of A Securities | Downgrade | Neutral → Underperform | $38 |
Total return (dividends reinvested) (ALKS)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +47.1% | +43.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +47.3% | +7.4% |
| Volatility (annualized) | 40.2% | 36.8% |
| Max drawdown | -29.2% (Jul 2026→Oct 2026) | -30.5% (Jul 2022→Oct 2022) |
ALKS revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product | $411.7M | 83.0% | +34.0% |
| — Vivitrol (part of Product) | $124.5M | 25.1% | +2.3% |
| — Aristada & Aristada Initio (part of Product) | $96.7M | 19.5% | -4.5% |
| — LUMRYZ (part of Product) | $96.6M | 19.5% | — |
| — LYBALVI (part of Product) | $94.0M | 18.9% | +11.5% |
| Manufactured Product & Royalty | $84.3M | 17.0% | +1.0% |
| — Royalty (part of Manufactured Product & Royalty) | $63.4M | 12.8% | -5.2% |
| — Manufacturing Revenue (part of Manufactured Product & Royalty) | $20.9M | 4.2% | +26.2% |
| Total revenue | $496.0M | 100% | — |
ALKS revenue by region (fiscal year ended Dec 31, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $1.37B | 93.0% | -2.7% |
| Foreign Country Excluding Specified Country | $102.4M | 6.9% | -30.0% |
| Ireland | $754,000 | 0.1% | -41.7% |
| Total revenue | $1.48B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
ALKS suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Novo Nordisk (NVO) | “In May 2024, we completed the sale of our Athlone Facility and related business to Novo Nordisk ("Novo") and entered into subcontracting arrangements to continue certain development and manufacturing activities performed at the Athlone Facility for a period of time after the closing of the transaction, which concluded by the end of 2025.” |
| Partner | Janssen | “Under an exclusive license agreement with Janssen, we provided Janssen with rights to, and know-how, training and technical assistance in respect of, our small particle pharmaceutical compound technology, known as NANOCRYSTAL technology, which was used to develop the long-acting INVEGA products, and we received milestone payments from Janssen upon the achievement of certain development goals.” |
| Partner | Avadel Pharmaceuticals | “In October 2025, we entered into the Transaction Agreement with Avadel, which was subsequently amended in November 2025, pursuant to which we agreed to acquire the entire issued and to be issued ordinary share capital of Avadel for consideration of (i) $21.00 per Avadel Share, payable in cash at closing and (ii) a non-transferable CVR entitling holders of Avadel Shares to a potential additional cash payment of $1.…” |
| Competitor | Eli Lilly (LLY) | “In the treatment of schizophrenia, ARISTADA, the long-acting INVEGA products and RISPERDAL CONSTA compete with each other and a number of other injectable products, including ZYPREXA RELPREVV ((olanzapine) For Extended Release Injectable Suspension), which is marketed and sold by Lilly;” |
| Competitor | Johnson & Johnson (JNJ) | “In the treatment of schizophrenia, LYBALVI competes with other oral antipsychotic products, including CAPLYTA (lumateperone) marketed by Johnson & Johnson or its affiliated companies.;” |
Quoted from the company's 10-K filed Feb 25, 2026.
Companies that name ALKS in their SEC reports
| Relationship to ALKS | Company | Filing | Sentence |
|---|---|---|---|
| supplier | VEEVA SYSTEMS INC (VEEV) | 10-K Mar 20, 2026 | “Our life sciences customers range from the largest global pharmaceutical and biotechnology companies such as Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharma AG, to emerging growth pharmaceutical and biotechnology companies, including Alkermes Inc., Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and Idorsia Pharmaceuticals Ltd. We…” |
ALKS customer concentration
In the period ended Dec 31, 2025, 3 direct customers each accounted for at least 10% (31%, 20%, 17%) of revenue, per the company's 10-K filed Feb 25, 2026. The company does not name them.
ALKS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.25 | $0.36 | -31.6% | $465.1M | 4 |
| Next quarter (ends Dec 2026) | $0.09 | $0.32 | -72.0% | $472.3M | 4 |
| Current fiscal year (ends Dec 2026) | $1.27 | $0.98 | +29.6% | $1.82B | 4 |
| Next fiscal year (ends Dec 2027) | $1.81 | $1.56 | +16.2% | $1.94B | 4 |
ALKS options: expected move
Options price a move of about ±11.0% (±$4.85) by Nov 20, 2026, which includes earnings on Nov 3, 2026. Over the last 8 reports the stock moved ±6.1% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 48.8% | ±11.0% |
| Dec 18, 2026 | 56 | 50.7% | ±15.9% |
| Jan 15, 2027 | 84 | 49.3% | ±19.1% |
| Feb 19, 2027 | 119 | 49.6% | ±22.5% |
| May 21, 2027 | 210 | 51.6% | ±30.7% |
30-day implied volatility 48% vs 38.4% realized over the last 30 trading days. Put/call ratio (volume) 0.06. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 11:23 UTC)
| Price | USD 44.18 |
|---|---|
| Change | ▲ 1.61% (up) |
| Previous Close | USD 43.48 |
| Open | USD 44 |
| Day Range | USD 43.46 – 44.68 |
| 52-Week Range | USD 27 – 55.67 |
| Volume | 1,833,975 shares |
| Market Cap | $7.41B |
| Exchange | NMS |
Technical Analysis (ALKS)
Nexqual's technical model rates ALKS "NEUTRAL" based on 3 bullish and 4 bearish signals across 127 daily candles, as of October 23, 2026 at 11:23 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 57.22 (neutral) |
| vs SMA50 | Below (USD 44.61) |
| MACD | -0.35 (negative) |
Analyst Ratings (ALKS)
Wall Street analysts rate ALKS "Buy" based on 20 analysts, with a mean price target of USD 56.21 (range USD 38–83), per Nexqual as of October 23, 2026 at 11:23 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 20 |
| Mean Target | USD 56.21 |
| High Target | USD 83 |
| Low Target | USD 38 |
| Buy / Hold / Sell | 15 / 4 / 1 |
Earnings (ALKS)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD 0.25 |
| Revenue Estimate | $465.11M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.7 vs est 0.29 ▲ beat |
| 2026-03-31 | USD 0.38 vs est -0.04 ▲ beat |
| 2025-12-31 | USD 0.48 vs est 0.45 ▲ beat |
| 2025-09-30 | USD 0.65 vs est 0.39 ▲ beat |
Source: Nexqual, October 23, 2026 at 11:23 UTC.
Financials & Fundamentals (ALKS)
| Total Revenue | $1.67B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +27.00% |
| Gross Margin | +87.18% |
| Operating Margin | +15.50% |
| Profit Margin | +3.96% |
| ROE | +3.85% |
| Debt / Equity | 0.87 |
| Current Ratio | 2.3 |
| Total Cash | $656.58M |
| Total Debt | $1.57B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $221.65M (13.3% of revenue) |
Source: Nexqual, October 23, 2026 at 11:23 UTC.
Financial Health Score (ALKS)
Nexqual rates Alkermes plc's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 11:23 UTC.
| Growth | Weak — Revenue -5% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 87%, operating 15% (last 12 months) |
| Balance Sheet | Mixed — $657M cash and investments vs $1.52B debt (Jun 2026, SEC) |
| Cash Flow | Solid — FCF $222M (last 4 quarters to Jun 2026, SEC), 13% margin |
| Efficiency | Weak — ROE 4%, ROA 4.2% |
Ownership (ALKS)
| Insider Ownership | +1.40% |
|---|---|
| Institutional Ownership | +107.78% |
| Shares Outstanding | 167.76M |
| Float | 155.19M |
| Short % of Float | +14.72% |
Source: Nexqual, October 23, 2026 at 11:23 UTC.
Leadership (ALKS)
Alkermes plc is led by Blair C. Jackson, President, CEO & Director, per Nexqual as of October 23, 2026 at 11:23 UTC.
| President, CEO & Director | Blair C. Jackson |
|---|---|
| Senior VP & CFO | Joshua Reed |
| Senior Vice President of Corporate Affairs & Investor Relations | Sandra Coombs |
Major Backers & Investors (ALKS)
Notable institutional backers of Alkermes plc include Baker Bros. Advisors, LP, Price (T.Rowe) Associates Inc, Renaissance Technologies, according to Nexqual as of October 23, 2026 at 11:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baker Bros. Advisors, LP | 5.97% |
| Price (T.Rowe) Associates Inc | 4.02% |
| Renaissance Technologies | 3.85% |
| Deep Track Capital, Lp | 2.38% |
| Fidelity | 1.09% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 17.43% |
| Vanguard Group | 10.14% |
| State Street | 5.46% |
| Geode Capital | 2.67% |
| Dimensional Fund Advisors | 2.5% |
Source: Nexqual, October 23, 2026 at 11:23 UTC.
From Alkermes plc's Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- The following provides summary information regarding our proprietary products that we commercialize: The following provides summary information regarding certain key third-party products using our proprietary technologies under license and our key licensed product, that are commercialized by our licensees: We have developed and now commercialize products designed to help address the unmet needs of people living with opioid dependence, alcohol dependence, schizophrenia and bipolar I disorder.
- We have used our proprietary technology platforms, which include technologies owned and exclusively licensed to us, to establish drug development, clinical development and regulatory expertise and in the development of our products.
- We purchase LUMRYZ API and outsource the manufacturing of LUMRYZ drug product to several contract manufacturers in the U.S. and outside of the U.S.
- In such cases, our licensee usually holds the relevant marketing authorization from the FDA or other relevant regulatory authority, and we support this authorization as needed, including by furnishing a copy of the product's Drug Master File, or chemistry, manufacturing and controls data, to the relevant regulator.
Partnerships
- Under an exclusive license agreement with Janssen, we provided Janssen with rights to, and know-how, training and technical assistance in respect of, our small particle pharmaceutical compound technology, known as NANOCRYSTAL technology, which was used to develop the long-acting INVEGA products, and we received milestone payments from Janssen upon the achievement of certain development goals.
- Pursuant to the settlement and license agreement entered into between Jazz and Avadel in October 2025 (the "Avadel Settlement Agreement"), from October 1, 2025, Jazz receives a royalty of 3.85% (subject to certain adjustments set forth in the agreement) on net sales of LUMRYZ sold for narcolepsy and additional royalties on net sales of LUMRYZ sold for any other future FDA-approved non-narcolepsy indications.
Legal & Regulatory Risks (Item 1A, quoted)
- Litigation or arbitration filed against Alkermes, including securities litigation, or actions (such as citizens petitions) filed against regulatory agencies in respect of our products, may result in financial losses, harm our reputation, divert management resources, negatively impact the approval of our products, or otherwise negatively impact our business.
- We are, and may in the future become, involved in various legal proceedings, including those asserting violations of securities and/or fraud and abuse laws and those asserting claims related to product liability, class actions or antitrust claims, IP and/or contractual arrangements.
- We have been, and may again be, the subject of citizen petitions or litigation that request that the FDA refuse to approve, delay or withdraw approval of, or impose additional approval requirements on our marketing applications.
- The clinical study or commercial use of our products may cause unintended side effects or adverse reactions, or incidents of misuse may occur, which could adversely affect our products, business and share price.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AMRX | Amneal Pharmaceuticals, Inc. | USD 20.48 | ▲ 1.39% |
| HIMS | Hims & Hers Health, Inc. | USD 29.13 | ▼ 0.27% |
| LNTH | Lantheus Holdings, Inc. | USD 100.1 | ▼ 0.14% |
| KNSA | Kiniksa Pharmaceuticals Interna | USD 80.79 | ▲ 1.37% |
| RDY | Dr. Reddy's Laboratories Ltd | USD 13.23 | ▲ 0.3% |
| RGC | Regencell Bioscience Holdings L | USD 9.81 | ▼ 9.17% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 11:23 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt